stockrow
Wednesday 4 November 2026
Export ENTX’s income statement to Excel — free account
Entera Bio Ltd.
ENTX Healthcare Biotechnology
Entera Bio Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $42,000.00, down 76.8% from fiscal 2024.
- Revenue
- +200.0%
- EPS
- −133.3%
- Free cash flow
- −108.9%
Quarter to June 2026, against a year earlier
3.14
0.09
+2.95%
Follow ENTX
Alert me
Entera Bio Ltd. (ENTX) P/E ratio
Entera Bio Ltd. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2025 | 0.0× | — |
| Dec 2024 | 0.0× | — |
| Sep 2024 | 0.0× | — |
| Jun 2024 | 0.0× | — |
| 16 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NGNE Neurogene Inc. compare | n/m |
| INDP Indaptus Therapeutics, Inc. compare | n/m |
| STTK Shattuck Labs, Inc. compare | n/m |
| BCAX Bicara Therapeutics Inc. compare | n/m |
| ENTX Entera Bio Ltd. | n/m |
| ACRS Aclaris Therapeutics, Inc. compare | n/m |
| CYVNY Ceryvyn Therapeutics Ltd. - Unsponsored ADR compare | n/m |
| PBYI Puma Biotechnology, Inc. compare | 18.9× |
| ANL Adlai Nortye Ltd. Sponsored ADR compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.6× |
| Market median | 18.3× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)